ACSL4 and hepatocellular carcinoma: CPT1A can downregulate ACSL4 expression and the downregulation of ACSL4 has been found to mediate ferroptosis‐related resistance to sorafenib in HCC or oxaliplatin in colorectal cancer (CRC) [29, 80, 81].